MUC1 and primary cutaneous T-cell non-Hodgkin lymphoma: Additionally, a xenograft murine model of CTCL showed that DAC and Mucin-1 C-terminal subunit inhibition (GO-203) resulted in a significant reduction in tumor volume compared to either agent alone (10).